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MOTHER STILL KNOWS BEST:
CANCER-RELATED GENE MUTATIONS,
FAMILIAL PRIVACY, AND A PHYSICIAN'S
DUTY TO WARN
Alissa Brownrigg*
Whatever, in connection with my professional service, or not in
connection with it, I see or hear, in the life of men, which ought
not to be spoken of abroad, I will not divulge, as reckoning that
all such should be kept secret.'
Introduction
At the completion of medical school, graduates embarking on
their careers as physicians mark the moment by taking the Hippo-
cratic Oath.2 Although the oath originated as early as the fifth cen-
tury B.C., its vow to abstain from sharing a patient's personal
information remains an important tenet of medical care today.
The oath's assurance of privacy encourages patients to divulge per-
sonal information, trusting that their doctors will keep it confiden-
tial, even from members of the patients' families.4
* J.D. Candidate, Fordham University School of Law, 1999; B.A., magna cum
laude, Barnard College, 1996; A.D.N., University of Hawai'i, Manoa, 1988. I would
like to extend my appreciation to Professor Elizabeth Cooper for her valuable insight
and advice and Radford Small for providing endless encouragement.
1. Oath and Law of Hippocrates (visited Nov. 24, 1998) <ftp://ftp.std.com/obi/
Hippocrates/HippocraticOath>.
2. See Robert D. Orr & Norman Pang, The Use of the Hippocratic Oath: A Re-
view of 20th Century Practice and a Content Analysis of Oaths Administered in Medi-
cal Schools in the U.S. and Canada in 1993 (visited Feb. 19, 1998) <http://www.sequel.
net/-twilight/poath9.htm> (noting that while a majority of medical schools do adminis-
ter a version of the oath that omits outdated content of the traditional oath, some
schools do not administer the Hippocratic Oath at all).
3. See Charles Marwick, Medical Records Privacy a Patient Rights Issue, 276
JAMA 1861 (1996) ("A patient has a right to keep personal medical information con-
fidential .... [T]he best guide for steering a path way through today's computerized
medical recordkeeping is the Hippocratic oath."); American Medical Association-
Institute for Ethics, Principles of Medical Ethics (visited Nov. 24, 1998) <http://www.
ama-assn.org/ethic/pome.htm> ("A physician shall ... safeguard patient confidences
within the constraints of the law.").
4. See Marwick, supra note 3 ("Plans with a more cavalier attitude to privacy will
not attract members, who will switch to other plans if they can or withhold informa-
tion about their health if they can't.") (citation omitted); Bernard Friedland, Physi-
cian-Patient Confidentiality; Time to Re-Examine a Venerable Concept in Light of
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In situations where confidential medical information affects the
health of a patient's relatives, however, some assert that physicians
should be required to share the information with the family, with
or without the patient's consent.5 The patient's children particu-
larly may benefit from the medical information, especially where it
reveals a genetic disease, because a forewarning of their increased
risk of the disease would give them the option of investigating and
taking advantage of preventive measures.6
This conflict between protecting the integrity of physician-pa-
tient confidentiality and protecting at-risk third parties lies at the
core of many medical-legal conflicts.7 For example, since the turn
of the century, physicians treating patients for communicable dis-
eases, such as tuberculosis, have had to decide whether the interest
of third parties (or the public at large) to be warned of -a risk of
infection or harm from the disease supersedes the duty to maintain
the confidentiality of the patient's information for the patient.'
Contemporary Society and Advances in Medicine, 15 J. LEGAL MED. 249, 256 (1994)
("The patient's most profound secrets are kept confidential. This encourages patients
to bare themselves fully to their physicians so that an accurate diagnosis may be made
and appropriate treatment instituted.").
5. See Diana Brahams, Human genetic information: the legal implications, in
HUMAN GENETIC INFORMATION: SCIENCE, LAW AND ETHICS 111, 113-14 (Derek
Chadwick et al. eds., 1990).
As against the duty of confidentiality which would be owed by a doctor,
there may be a duty of disclosure to a partner or child which has to be
weighed in the legal balance, particularly if all concerned are patients of the
same doctor who owes them all an equal duty of care. In this instance, unless
the public are put at risk, any disputes which arise are likely to be private
matters.
Id.
6. See Lori B. Andrews, Torts and the Double Helix: Malpractice Liability for
Failure to Warn of Genetic Risks, 29 Hous. L. REV. 149, 180 (1992) [hereinafter
Double Helix] ("The strongest case for a warning exists when there is a high likeli-
hood that the relative has the genetic defect, the defect presents a serious risk to the
relative and his or her children, and presumably the disclosure is necessary to prevent
serious harm.").
7. See id. at 176 ("A major exception to confidentiality, however, should be
noted. A physician may, in certain instances, breach confidentiality in order to protect
third parties from harm, such as when the patient might transmit a contagious disease
or commit violence against an identifiable individual."); see generally Friedland, supra
note 4 (examining the numerous circumstances where conflict arises between the legal
and ethical obligations of physicians to protect the confidentiality of patients' infor-
mation and the potential benefit to third parties if such information is made available
to them).
8. See Susan Fox Buchanan, Medical Ethics at the Millennium: A Brief Retrospec-
tive, 26 COLO. LAW. 141, 142 (1997) ("[U]rbanization in the late nineteenth and early
twentieth centuries led to a growing concern with public health and epidemics in
many American new cities .... [C]onfidentiality had been tempered by the exigen-
cies of contagious disease."); Philip R. Reilly, Public Policy and Legal Issues Raised
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Although respect for a patient's privacy generally compels doctors
to refrain from sharing medical information with anyone
uninvolved with the patient's care, the physician must notify health
officials when innocent third parties are at risk of certain diseases.9
Recently, physicians who treat HIV-positive individuals have faced
this conflict because they now may notify at-risk partners or con-
tacts (i.e., intravenous drug users with whom the individual has
shared needles) if the patient does not.10 In the near future, ge-
netic test results may create another exception to physician-patient
confidentiality because of their potentially valuable use to close pa-
tient relatives.'1
Although genetic testing has existed for many years,' 2 scientists
are presently attempting to identify the patterns created by all
human genes. 13 Researchers are linking these patterns with inher-
by Advances in Genetic Screening and Testing, 27 SUFFOLK U.L. REV. 1327, 1334-35
(1993) (comparing genetic privacy considerations with those of HIV information;
there, individual privacy rights often outweigh disclosure to third parties with strong
interest in information).
9. See infra note 95 and accompanying text.
10. See infra note 99 and accompanying text.
11. See Sonia M. Suter, Whose Genes Are Those Anyway? Familial Conflicts Over
Access to Genetic Information, 91 MICH. L. REV. 1854, 1854-55 (1993) ("[T]he identi-
fication of disease genes has escalated dramatically .... [C]onflicts of interest may
arise between an individual and her relatives, who may personally benefit from learn-
ing about the individual's genetic status."); Genetics in the Courtroom: An Introduc-
tion, 36 No. 3 JUDGES' J. 1 (1997) (recognizing that genetic discoveries promise to
introduce new types of evidence, causes of action and perspectives into courtrooms);
Andrews, Double Helix supra note 6, at 177.
One can make an argument that health care professionals working in the
medical genetics field have disclosure obligations similar to those of the phy-
sician whose patient suffers from an infectious disease or a psychotherapist
whose patient is a [sic] potentially violent. Because of the inheritable nature
of genetic diseases, a health professional who, through research, counseling,
examination, testing, or treatment, gains knowledge about an individual's
genetic status invariably has information valuable not only to the patient,
but also to his or her spouse or relatives.
Id.
12. See ROGER B. DWORKIN, LIMITS: THE ROLE OF LAW IN BIOETHICAL DECI-
SION MAKING 85 (1996) (noting that since the 1953 discovery of DNA's structure,
genetic screening, counseling, and prenatal diagnosis have become established in
medical practices).
13. Genes are the functional units of DNA that combine into various patterns and
lead to different appearances and behaviors, or phenotypes, of cells. See Leroy Hood
& Lee Rowen, Genes, Genomes, and Society, in GENETIC SECRETS 4 (Mark A. Roth-
stein ed., 1997); U.S. CONGRESS, OFFICE OF TECHNOLOGY ASSESSMENT, TECHNOLO-
GIES FOR DETECTING HERITABLE MUTATIONS IN HUMAN BEINGS 6 (1986)
(describing the human genome, which is the complete set of genetic information-
each cell of the human body contains forty-six chromosomes, where groups of genes
are arranged in sequence to form DNA and proteins).
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ited traits, disease, and even an individual's susceptibility to com-
mon adult-onset disease. 14 So far, genetic mutations have been
identified and linked to several diseases, such as Alzheimer's, vari-
ous cancers, and Lou Gehrig's Disease. 15 Genetic testing is fre-
quently used in prenatal testing and will increasingly become
available to the public as part of routine health care.16
BRCA1 7 and BRCA218 'are recently discovered genetic muta-
tions that signal that their carriers face a risk of developing breast
and ovarian cancer that is significantly higher than the risk the av-
erage woman faces. 19 As more women become aware of the
BRCA mutations, there will be an increased demand for BRCA
14. Adult-onset, or late-onset diseases are those that are present in an individual's
DNA since conception, but do not manifest themselves until adult life. See Wendy C.
McKinnon et al., Predisposition Genetic Testing for Late-Onset Disorders in Adults: A
Position Paper of the National Society of Genetic Counselors, 278 JAMA 1217, 1217
(1997); OFFICE OF TECHNOLOGY ASSESSMENT supra note 13, at 30.
15. See Michael J. Malinowski & Robin J.R. Blatt, Commercialization of Genetic
Testing Services: The FDA, Market Forces, and Biological Tarot Cards, 71 TUL. L.
REV. 1211, 1224 (1997) ("Recent discoveries include genetic links to Alzheimer's,
bladder cancer, cervical cancer, colon cancer, obesity, prostate cancer, and tumor
growth associated with a spectrum of common cancers. Researchers are even devel-
oping an 'Ides of March' genetic test to serve as a crude indicator of a person's life
span."); Julie Holland, Should Parents be Permitted to Authorize Genetic Testing for
their Children? 31 FAM. L. Q. 321, 324 (1997).
16. See John Bell, Prenatal Diagnosis: Current Status and Future Trends, in
HUMAN GENETIC INFORMATION: SCIENCE, LAW AND ETHICS, SYMPOSIUM ON HUMAN
GENETIC INFORMATION; CIBA FOUNDATION SYMPOSIUM 18, 19 (1992).
Genetic Screening, as it is currently applied, relates mostly to the prenatal
diagnosis of the major monogenic disorders ... a number of technological
advances ... will introduce the possibility of effectively screening for many
common diseases. In turn, this will alter both the populations needing to be
screened and the potential interventions that follow such screening
procedures.
Id.; Benjamin S. Wilfond & Kathleen Nolan, National Policy Development for the
Clinical Application of Genetic Diagnostic Technologies: Lessons from Cystic Fibrosis,
270 JAMA 2948, 2949 (1993) ("It may... seem inevitable that virtually every test that
is technically feasible will be routinely used. Commercial interests may promote test-
ing; clinicians may use tests to allay fears of legal liability; and patients themselves
may demand testing to obtain genetic information.").
17. See infra note 35 and accompanying text.
18. See infra note 36 and accompanying text.
19. See Wylie Burke, Recommendations for Follow-up Care of Individuals With an
Inherited Predisposition to Cancer: II. BRCA1 and BRCA2, 277 JAMA 997, 998
(1997) [hereinafter Recommendations III. Although BRCA1 is associated with a six
percent lifetime risk of colon cancer in women and men, and an eight percent lifetime
risk of prostate cancer in men, both BRCA1 and BRCA2 are blamed for significant
increases in breast cancer, a disease most commonly experienced by women, and ova-
rian cancer, a disease exclusively experienced by women. See id. See infra notes 35
and 36 and accompanying text. Because I concentrate on breast and ovarian cancers,
I will use "patient" to refer to females throughout the Note.
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testing.20 Accordingly, physicians will more frequently face the di-
lemma of whether to notify family members of their increased risk
of developing cancer due to their genetic makeup. Geneticists,
however, have been unable to decide whether genetic information
should be disclosed to relatives because information has the poten-
tial for both great benefit and harm to its recipients.21 Therefore, a
balancing test is needed to govern the release of genetic data.22
This Note focuses on the BRCA gene mutations and argues that
physicians currently have no duty to warn the children23 of a
known BRCA carrier, who has been diagnosed with breast or ova-
rian cancer, that they also may carry the BRCA mutations that pre-
dispose them to cancer. Part I provides a background of current
genetic research and testing, including the significance of testing
positive for BRCA1 or BRCA2, and the future of BRCA testing.
Part II reviews current legislation regulating the dissemination of
genetic information, existing exceptions to physician-patient confi-
dentiality, and recent court decisions regarding the physician's duty
20. See Nancy Press et al., How are Jewish Women Different From All Other Wo-
men?, 7 HEALTH MATRIX 135, 159 (1997).
We suggest that there is an implicit belief in the contemporary United States
that a probability statistic, accurately calculated and named, can eliminate its
own most essential element-uncertainty. This belief makes Americans see
risk information as inherently useful and may be one of the reasons there is
often insufficient attention paid to gaps between diagnostic sophistication
and treatment options. This is particularly relevant in the case of genetic
susceptibility testing for breast cancer because this belief may drive both
clinicians and test consumers to opt for genetic testing even in the absence of
proven efficacy of treatment sequelae.
Id.
21. See Dorothy C. Wertz, Society and the Not-So-New Genetics: What are We
Afraid of? Some Future Predictions from a Social Scientist, 13 J. CONTEMP. HEALTH
L. & POL'Y 299, 312 (1997) ("Whether or not to inform a patient's relatives that they
may be at a genetic risk, against the wishes of that patient, was one of the questions
geneticists found most difficult to answer. There was no consensus on this issue any-
where in the world.").
22. Although legislation is forward-looking, and a balancing test would be used by
a court after harm has occurred, solutions that succeed today will likely prove un-
workable for a long term in the realm of rapid advances in genetic technology. There-
fore, physicians could consider factors in the balancing test to determine whether or
not to disclose genetic information. See DWORKIN, supra note 12, at 12 ("Changing
values, advances in science, and unanticipated situations combine to create the possi-
bility that prospective, comprehensive lawmaking will be fundamentally flawed.").
23. Throughout this Note, references to a patient's children mean adult offspring.
Warning minor children about the possibility that they may inherit genetically linked
diseases raises numerous complex ethical issues that merit their own separate discus-
sion. For an excellent overview of these issues, see Dorothy C. Wertz et al., Genetic
testing for children and adolescents: who decides?, 272 JAMA 875 (1994); see also
Holland, supra note 15.
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to warn family members of genetic disease. Part III proposes a
balancing test which should be used to determine whether a physi-
cian is required to notify a patient's children if she tests positive for
a BRCA mutation. This test allows the physician's duty to warn to
adapt to changes in professional education, cancer prevention, and
legislation. This Note concludes that application of the balancing
test to BRCA mutations under current conditions indicates that
physicians should keep their patients' genetic information confi-
dential because of the substantial harm posed by its release.
I. A Background of Genetic Research
A brief overview of recent genetic research and advances in bio-
technology will illuminate areas where new exceptions in the confi-
dential nature of the physician-patient relationship may be
permitted. This Part reviews the developments in genetic research,
particularly with respect to the BRCA1 and BRCA2 mutations.
A. The Human Genome Project
The Human Genome Project ("HGP") is an international re-
search effort designed to locate and map out all human genes, col-
lectively known as the human genome.24 Once the human genome
is completely sequenced, scientists will have a "virtual instruction
book" for a human being.25 Genetic information details an individ-
ual's behavioral and biological traits, and diagnoses and reveals
24. Hearings on the National Genome Research Institute, 105th Cong. (1997) [here-
inafter Hearings on NHGRI] (Testimony of Francis S. Collins, Director of the Na-
tional Human Genome Research Institute) ("NHGRI"). In the United States, the
project is carried out by the NHGRI and the Department of Energy. The NHGRI,
which was established in 1989, funds research laboratories throughout the United
States and also has its own in-house laboratories. The HGP researchers intend to
sequence all human genes by the year 2005, and at the present time, have mapped out
about two percent of human DNA. See Human Genome Project Information (visited
Nov. 14, 1997) <http://www.ornl.gov/TechResources/HumanGenome/genetics.html>
(estimating that about 5800 genes have been mapped to date).
25. See Hearings on NHGRI, supra note 24. As researchers identify gene patterns
and mutations of those patterns, they also hope to determine what role environmental
influences may play in conjunction with inherited factors in the development of dis-
ease. With this information, scientists may reveal modes of preventing such diseases
as cancer, heart disease and diabetes that do not yet exist. See id.; see also EUGENE B.
BRODY, BIOMEDICAL TECHNOLOGY AND HUMAN RIGHTS 129 (1993) ("A detailed
chart of the genes is essential to ultimate progress in understanding the biology of
living organisms and, specifically, to the clinical biotechnology aimed at the preven-
tion and cure of genetic disease.").
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predispositions to certain diseases.2 6 Thegovernment, therefore,
has recognized that many moral, ethical, and legal issues arising
out of genetic research must be addressed in the near future.27
In an effort to identify and confront these questions, the Na-
tional Human Genome Research Institute ("NHGRI") created
and funded the Ethical, Legal, and Social Implications Program
("ELSI").28 ELSI's priorities include ensuring privacy and fair use
of genetic information, promoting responsible clinical integration
of genetic technologies, addressing ethical issues in research, and
educating professionals and the public about genetic issues.2 9 The
stated goals of ELSI are to identify issues resulting from genetic
research and develop policies to address these issues.30 The pro-
gram also seeks to foster an acceptance of genetic variation, and to
increase public and professional awareness of genetic testing and
the appropriate use of test results.3'
In addition to mapping normal gene patterns, the process of
identifying genes and their components, called nucleotides,32 also
26. McKinnon et al., supra note 14, at 1217 (noting that genetic tests which have,
in the past, detected rare monogenic conditions, can now identify susceptibility to
many complex, adult-onset diseases).
27. See F. Collins & D. Galas, A new five-year plan for the U.S. Human Genome
Project, 262 SCIENCE 43 (1993) (noting that the Department of Energy and the Na-
tional Institute of Health devote three to five percent of their annual budgets towards
ELSI, the world's biggest bioethics program).
28. Id.
29. See Hearings on NHGRI, supra note 24. Responding to the recommendations
of the ELSI group and to the National Action Plan on Breast Cancer, President Clin-
ton has stated that his administration will support legislation designed to prevent dis-
crimination by insurance companies on the basis of genetic information. See id.
30. See Francis S. Collins, Preparing Health Professionals for the Genetic Revolu-
tion, 278 JAMA 1285, 1285 (1997) [hereinafter Revolution].
31. Commentators have expressed great concern about physicians anxious to pro-
vide genetic testing to their patients and about the public demanding testing before
providers are adequately educated about interpreting test results and are trained to
provide sufficient counseling and support for their patients. See Malinowski & Blatt,
supra note 15, at 1245-1246.
[D]ue to the absence of clinical data, health care providers cannot interpret
the results of predictive genetic tests for most of their patients with any relia-
bility even when they are knowledgeable about genetics. This interpretation
problem is exacerbated because the current generation of health care prov-
iders does not possess such knowledge.
Id.
32. Nucleotides are the building blocks of genes. There are four different compo-
nents which bind together in pairs to form triplet formations called codons, which
make up amino acids, the components of proteins. See OFFICE OF TECHNOLOGY As-
SESSMENT supra note 13, at 6. When a mutation occurs, one nucleotide substitutes
another in its place and creates a different protein. See id.
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reveals mutations in sequences that contribute to disease.33 The
ability to identify patterns associated with disease may enable
scientists to develop treatments and cures.34 Some incurable dis-
eases, such as cystic fibrosis, Huntington's Disease, and Tay-Sachs,
are caused by mutations in one chromosome, and thus the
probability that offspring will inherit these conditions can be accu-
rately determined.35 Other diseases, such as breast and ovarian
cancer, insulin-dependent diabetes, and coronary artery disease,
develop if certain genetic mutations exist in combination with envi-
ronmental factors that have not yet been identified.36 Therefore,
33. See Hood & Rowen, supra note 13, at 8-9 (noting that alterations in gene pat-
terns in chromosomes, known as polymorphisms, can identify genes that predispose to
disease).
34. See Collins, Revolution supra note 30, at 1285.
[K]nowledge of basic biological alterations underlying illnesses also offers
the best hope for strategies to override or repair them. Promising gene-
based strategies include drug therapy, which is used to nurture defective pro-
teins, and gene therapy, in which the gene is used as a pharmaceutical. Gene
discovery also allows elucidation of interactions between genes and between
genes and the environment.
Id.; Reilly, supra note 8, at 1327-28. The human genome is organized as approxi-
mately one hundred pairs of genes patterned on twenty-three pairs of chromosomes.
About three billion nucleotides, the building blocks of DNA, encode the genes which
instruct cells to produce proteins that carry out cell processes and direct our bodily
functions. Mutations in the genes can create disease by sending cells "wrong" infor-
mation. See id. Scientists are able to locate the mutations in genes, replicate the
patterns, splice in desired arrangements, and introduce these into cells to correct er-
rors resulting in some diseases. See id. Current research may allow scientists to de-
velop this gene therapy for more mutations and make available treatment that will
attack diseases in a manner that is more effective and less destructive to the body. See
William J. Polvino & W. French Anderson, Medicine, Gene Therapy, and Society, in
THE HUMAN GENOME PROJECT AND THE FUTURE OF HEALTH CARE 39, 40-42
(Thomas H. Murray et al. eds., 1996).
35. See Paul M. Schwartz, Privacy and the Economics of Personal Health Care
Information, 76 TEX. L. REV. 1, 19 (1997) ("[S]uch monogenic diseases, which affect
only a tiny fraction of the population, can now be effectively predicted, although not
cured."). While Huntington's Disease results from a dominant gene and can be
passed on from one parent, cystic fibrosis is caused by a recessive gene and is only
manifest when both parents are carriers of the trait. See Robert Williamson & Anna
M. Kessling, The Problem of Polygenic Disease, in HUMAN GENETIC INFORMATION:
SCIENCE, LAW AND ETHICS 63 (Ciba Foundation 1990).
36. CARSON STRONG, ETHICS IN REPRODUCTIVE AND PERINATAL MEDICINE 136
(1997). While certain genetic mutations determine that a person will develop a dis-
ease, such as Huntington's Disease, cystic fibrosis and hemophilia, other mutations
are multifactorial, meaning that only in combination with other external factors, such
as environmental influences, will a particular disease develop. See id. Accordingly,
these mutations determine that their carriers are susceptible to certain diseases, but
cannot conclusively predict their development. Before scientists can discover preven-
tive measures with which to deter the onset of these conditions, the external factors
which contribute to disease must also be ascertained. See id.
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the discovery of these mutations only signals an individual's poten-
tial for disease and does not guarantee its development. Moreover,
the predictive value of many tests that identify predisposition to
disease is currently undetermined due to a dearth of data about the
complex nature of these gene mutations.37
B. The BRCA Gene Mutations
Both the BRCA1 and BRCA2 genetic mutations, identified in
199438 and 199539 respectively, are associated with breast and ova-
rian cancer.40 Studies show that women carrying one of these mu-
tations, whose families have a history of breast or ovarian cancer,
face a seventy-six to eighty-seven percent risk of developing breast
cancer, and a thirty-two to eighty-seven percent risk of developing
ovarian cancer during their lifetimes. 41 Women in the general pop-
ulation, without either genetic mutation, face approximately a
twelve percent risk of breast cancer and a one and a half percent
chance of developing ovarian cancer during their lifetimes.42 While
37. See infra notes 138-139 and accompanying text.
38. See Georgia L. Wiesner, Clinical Implications of BRCA1 Genetic Testing for
Ashkenazi Jewish Women, 7 HEALTH MATRIX 3, 21-22 (1997) ("The BRCA1 gene is a
large, novel gene of unknown function that extends over 100,000 bases of genomic
DNA .... Early studies of breast tumors showed that the BRCA1 region was fre-
quently deleted in approximately twenty percent of breast tumors during the process
of tumorigenesis thereby indicating that it may function as a tumor suppressor
gene."). BRCA1 increases a woman's risk for both breast and ovarian cancer. Carri-
ers who have had breast cancer also have a forty-four percent chance of developing
ovarian cancer by the age of seventy. See Burke et al., supra note 19, at 998. This
mutation is also associated with prostate cancer in men and colon cancer in both men
and women. See id.
39. Breast Cancer (Genetics): Full Sequence of BRCA2 Cancer Gene Published,
CANCER BIOTECHNOLOGY WKLY, Mar. 18, 1996 ("BRCA2 is believed to be responsi-
ble for approximately 40 percent of early-onset, hereditary breast cancer."); Wiesner,
supra note 38, at 23 ("BRCA2 is associated with pre-menopausal female and male
breast cancer.").
40. See Burke et al., supra note 19, at 998. The BRCA2 mutation creates a similar
risk for breast cancer in women as BRCA1. See id. Researchers have observed sev-
eral cases of breast cancer in males carrying the BRCA2 mutation, with one pedigree
of the mutation linked to multiple cases of male breast cancer and none in females.
See id. The risk for ovarian cancer is increased to a lesser extent for women carrying
BRCA2 than for those with BRCA1. See id.
41. See Wiesner, supra note 38, at 21 (stating that cumulative breast cancer risk for
BRCA1 carriers is about 50% by age 50 and 85% by age seventy while risk for ova-
rian cancer is 30-40% by age sixty); Jeffrey Struewing et al., The Risk of Cancer Asso-
ciated with Specific Mutations of BRCA1 and BRCA2 Among Ashkenazi Jews, 336
NEW ENG. J. MED. 1401, 1401 (1997).
42. See Deborah Schrag et al., Decision Analysis-Effects of Prophylactic Mastec-
tomy and Oophorectomy on Life Expectancy Among Women with BRCA1 or BRCA2
Mutations, 336 NEw ENG. J. MED. 1465, 1465 (1997).
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only five to ten percent of all cases of breast cancer are attributed
to the BRCA mutations,43 a woman carrying one of these muta-
tions is twenty times more likely than a woman without the muta-
tions to develop breast cancer before the age of fifty.
4
"
C. Advantages of Undergoing Testing for the BRCA Mutations
Women identified as BRCA mutation carriers may take advan-
tage of several suggested measures that may prevent the onset of,
or increase the chances of surviving, breast or ovarian cancer.45
These preventive steps range from simple dietary or activity
changes to surgical intervention.46 Low-fat, high-fiber diets, regu-
lar exercise, and the avoidance of smoking may decrease the inci-
dence of breast cancer. 47 Because early detection greatly increases
the chances of surviving breast cancer, women are encouraged to
perform regular breast self-exams to monitor for any changes in
breast tissue.48
A health care provider also may perform breast exams during
annual check-ups and monitor for any tumorous growths through
regular mammograms.49 Women with a family history of breast
cancer are encouraged to have a baseline mammogram when they
reach the age of twenty-five, followed by routinely scheduled mam-
mograms throughout the remainder of their lives.5 0 Although
drugs have been proposed as agents to help prevent breast can-
cer,5 ' their efficacy is unproven, and more research is necessary
43. See Wiesner, supra note 38, at 15.
44. See Burke et al., Recommendations I!, supra note 19, at 997, 999.
45. See Jerome Groopman, Decoding Destiny, THE NEW YORKER, Feb. 9, 1998, at
44 (stating that measures to prevent cancer range from avoiding alcohol and fats,
drinking herbal tonics, and taking megavitamins, to the removal of breasts and
ovaries).
46. See id.
47. See Wylie Burke et al., Recommendations for Follow-up Care of Individuals
With an Inherited Predisposition to Cancer; I. Hereditary Nonpolyposis Colon Cancer,
277 JAMA 915, 918 (1997) (emphasizing that lifestyle changes have not been proven
effective, but may decrease risk of cancer for those with inherited predisposition to
cancer).
48. See Burke, Recommendations II, supra note 19, at 998-99 ("The limited sensi-
tivity of mammography, particularly in younger women, makes self-examination po-
tentially of greater value for BRCA1 and BRCA2 mutation carriers than for women
of average risk.").
49. See id.
50. See id. at 999 (warning that, although early testing is recommended for women
at high risk of breast cancer, risks and benefits of mammography before age fifty have
not yet been established).
51. See id. at 1001.
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before this strategy is routinely implemented.52 At the extreme,
women at high risk for breast cancer may even opt to undergo a
prophylactic mastectomy. 3
Fewer preventive measures exist for ovarian cancer because wo-
men diagnosed with this disease usually do not exhibit symptoms
until it significantly has advanced.5 4 Regular exercise and low-fat
[O]ral contraceptives may provide a means to reduce ovarian cancer risk. In
addition.... tamoxifen[ ] has been shown to reduce rates of recurrent and
contralateral breast cancer, suggesting a role for this agent in primary pre-
vention . . . [but it] has been shown to increase endometrial cancer risk,
cause bone marrow suppression, promote thrombotic events, and produce
an array of other unpleasant adverse effects.
Id. See also Mendel E. Singer & Randall D. Cebul, BRCA1: To Test or Not to Test,
That is the Question, 7 HEALTH MATRIX 163, 182 (1997).
52. See Joyce O'Shaughnessy, Chemoprevention of Breast Cancer, 275 JAMA
1349, 1353 (1996) (citing the identification of breast cancer susceptibility genes and
improved diagnostic tools for breast lesions as highlighting the need to develop effec-
tive intervention strategies against breast cancer). Because there are more opportuni-
ties for women to recognize their increased risk for breast cancer, there is a greater
push for scientists to develop pharmaceutical agents that may help prevent the devel-
opment of the disease. See id. While such research is in progress today, much more
must be conducted before drug therapy is readily available to those at risk. See id. at
1352-53.
53. A prophylactic mastectomy is the elective removal of one or both breasts
before any sign of tumor formation occurs for the purpose of preventing the onset of
breast cancer. See Schrag et al., supra note 42, at 1465. If diagnosed with cancer in
one breast, a woman may choose to have her doctor remove both the affected and
noncancerous breasts, so that she may avoid a recurrence of the cancer in the healthy
breast at some later time. See Diana Keough, Portraits of Prevention; Women with
Family History of Breast Cancer Choose to Have Mastectomies, THE PLAIN DEALER,
Sept. 1, 1997, at IF. Women from families at high risk for breast cancer also may
decide to have their breasts removed in an effort to prevent cancer. See id.
("Although the procedure has been performed since 1960 on women with a strong
family history of breast cancer-defined as two or more relatives with the disease-
the number of procedures has increased since the identification of the breast cancer
genes .... ). See also Schrag et al., supra note 42, at 1469 ("Until better methods of
cancer prevention are developed, women and their physicians are likely to continue to
consider the possibility and timing of prophylactic mastectomy and oophorectomy.").
54. See Dennis S. Chi & William J. Hoskins, Ovarian Cancer Controversy: When
and How to Use Available Screening Methods (visited Feb. 11, 1998) <http://www.
medscape.com/Medscape/womens.health/1996/vOl.nll/w172.chi/wI72.chi.html#Boxl>.
While screening is available for breast cancer (breast self-examination,
clinical breast examination, and mammography) and for colorectal cancers
(stool test for occult blood and sigmoidoscopy), no effective method has
been devised to screen for ovarian cancer ... [u]nfortunately, early in the
course of the disease, patients are either asymptomatic or have nonspecific
symptoms, such as abdominal discomfort, dyspepsia, or urinary frequency,
which may go unrecognized by both the patient and her physician for pro-
longed periods of time. Therefore, approximately 70% of patients present
with advanced ... stage disease.
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diets may help to prevent ovarian cancer, 55 but there is no self-
exam for physical changes (such as the presence of lumps), and
clinicians frequently do not detect abdominal masses before the
cancer has spread to other areas of the body. 6 Surveillance for
women at high risk for ovarian cancer, however, includes routine
ultrasounds and blood tests that may indicate tumor develop-
ment.5 ' These women also may elect to undergo a prophylactic oo-
phorectomy, or removal of the ovaries. 8 Indeed, one study shows
that roughly one-third of women carrying the BRCA1 mutation
who have a strong family history of breast or ovarian cancer plan
to have their ovaries removed to prevent cancer.59 This option is
not available to women who wish either to start a family or have
55. See Burke et al., Recommendations H, supra note 19, at 1001 ("Dietary and
exercise measures are an unproven means to reduce cancer risk, but have a broad
range of other health benefits and do not pose the risks of pharmacological or proce-
dural interventions.").
56. See Chi & Hoskins, supra note 53.
[T]he normal ovary is usually not palpable in postmenopausal women. Un-
fortunately, given the natural history of ovarian cancer, it has been estimated
that one must perform more than 10,000 routine pelvic exams to detect 1
case of ovarian cancer ... [s]uch reports demonstrate that pelvic examina-
tion is too insensitive to serve as the sole screening method to detect curable
stages of ovarian cancer.
Id.
57. See id. ("Prospective trials have provided data supporting the use of serum
tumor markers [found in the blood] and sonography in ovarian cancer screening for
at-risk patients.").
58. See Schrag et al., supra note 42, at 1470 ("In our analysis, prophylactic oopho-
rectomy resulted in, at most, small gains in life expectancy, and postponing oophorec-
tomy until the completion of childbearing reduces its benefit minimally.").
Prophylactic oophorectomy is the elective removal of both ovaries before any sign of
disease is detected. Id. Although this procedure currently provides the best mode of
prevention for ovarian cancer, it is not foolproof. See Chi & Hoskins, supra note 53.
A woman from a family with a hereditary ovarian cancer syndrome should
be offered the option of prophylactic oophorectomy after childbearing is
completed or by age 35. However, she needs to understand that although
prophylactic oophorectomy is presently the only effective method of ovarian
cancer prevention, there have been case reports of patients with hereditary
ovarian cancer syndromes who have ... subsequently developed [cancer].
Id.
59. See Caryn Lerman et al., BRCA1 Testing in Families With Hereditary Breast
Ovarian Cancer; A Prospective Study of Patient Decision Making and Outcomes, 275
JAMA 1885, 1891 (1996). When a parent or sibling carries the BRCA1 gene and
develops breast or ovarian cancer, other close family members may decide to undergo
genetic testing so that they can better determine how aggressive their efforts at
preventing the cancer should be. The 'decision whether or not to have breasts or ova-
ries removed, a measure some may consider quite drastic, may hinge on the presence
of genetic factors. Id. ("For members of HBOC [hereditary breast and ovarian can-
cer] families who do not carry a BRCA1 mutation, receipt of a negative test result
may prevent unnecessary prophylactic surgery.").
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another child, however, because the removal of the ovaries results
in menopause.6 °
D. The Future of BRCA Testing
While significant attention has focused on the advances in ge-
netic research and the availability of new genetic tests, there has
been little discussion about the potential harms that can result
from testing and the appropriate ways to deal with genetic infor-
mation.61 Despite the lack of thorough analysis regarding the com-
plex social, ethical, and legal implications of genetic testing, the
demand for and occurrence of testing will continue to rise.62
Breast cancer receives enormous media attention and has been
cited as the most important health concern of American women. 63
As more women with relatives diagnosed with breast or ovarian
60. See Burke et al:, Recommendations II, supra note 19, at 1001 ("Balanced
against the potential but unproven protective effect of oophorectomy are the risks
and symptoms of surgical menopause .... Treatment with hormone therapy to de-
crease these risks may increase risk of breast cancer.").
61. See Gail Geller et al., Genetic Testing for Susceptibility to Adult-Onset Cancer;
The Process and Content of Informed Consent, 277 JAMA 1467, 1468 (1997) (stating
that professional societies recommend that genetic testing be confined to clinical re-
search due to complex implications of results warranting special attention for in-
formed consent). Before health practitioners offer genetic testing to their patients, it
is important that they are educated about interpreting results and the need to provide
adequate counseling to ensure that the decision to learn one's carrier status is fully
informed. See also Susan Gilbert, Doctors Often Misread Results of Genetic Tests,
Study Finds, N.Y. TIMES, Mar. 26, 1997, at C4.
62. See Lerman et al., supra note 58, at 1891 ("[T]o the extent that the public is
educated about BRCA1 testing and the potential benefits are emphasized, utilization
of BRCA1 testing is likely to increase."); Malinowski & Blatt, supra note 15, at 1217-
18 (stating that every person has four or five genetic mutations linked to serious
health conditions, and continued. research will uncover more links between genes and
diseases).
63. See Barbara Brotman, Fear of Breast Cancer Exaggerates its Impact, CHI.
TRIB., Oct. 5, 1997, at 9. Campaigns designed to increase the interest and awareness
of breast cancer have brought the disease to the forefront of public attention. Some-
times criticized for taking the focus off of other serious threats to the health of Ameri-
can women, the attention paid to breast cancer by newspapers, magazines and even
political leaders has significantly increased concern about prevention and desire for
early detection of the disease. See id. ("Breasts are also far more visible than, say,
lungs, sites of a cancer that kills more women than breast cancer. Women can hardly
avoid their breasts, especially when public health campaigns have turned morning
showers into diagnostic sessions."); see also Clintons Promote Cancer Detection: Presi-
dent and Wife Share Radio Address, ST. Louis POST-DISPATCH, Oct. 26, 1997, at 06A
(announcing higher standards for breast cancer screening); Celebrating Survivorship:
Making a Difference in the Fight Against Breast Cancer, NEWSWEEK, Oct. 13, 1997, at
S1 (finding that outreach and educational resources for breast cancer encourage wo-
men to screen for and prevent cancer).
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cancer learn about the tests for BRCA mutations, more physicians
will be asked to provide such screening.64
Physicians soon will find that they have access to these tests, be-
cause biotechnology companies already are marketing BRCA test-
ing kits.65 Moreover, as testing for BRCA mutations becomes
more accessible, people likely will use the information to direct
their life decisions, such as where to live, what occupation to
choose, and whether to have children. 66 There even has been spec-
ulation that women increasingly will ask to include screening for
the BRCA mutations in their prenatal testing.67
64. See Press et al., supra note 20, at 153.
[W]e have women, especially young, educated women, who are terrified of
breast cancer and overestimate their own vulnerability to the disease. Their
sense of risk is created and reinforced by media presentations of breast can-
cer which also accustoms them to thinking in terms of 'risk factors.' Since
many of the most frightened women also may be those with the best access
to health care services, we would suggest that a highly motivated set of con-
sumers exists for anything which they believe may reduce their risk of breast
cancer.
Id.; Many People Prefer Not to Know if They Have Gene Linked to Cancers, CANCER
WKLY, July 15, 1996 (stating more requests for BRCA1 test results came from study
subjects with health insurance, more relatives affected with breast cancer and more
knowledge about testing); but see George C. Cunningham, A Public Health Perspec-
tive on the Control of Predictive Screening for Breast Cancer, 7 HEALTH MATRIX 31,
47 (1997).
The media can contribute positively or negatively .... [B]y reporting new
discoveries they raise expectations. By publicizing the commercial availabil-
ity of tests, the media can create a demand for testing. However, by care-
fully reporting the limitations of current testing knowledge, they can
contribute to informed participation by the public in the formation of policy.
Id.
65. See Malinowski & Blatt, supra note 15, at 1212-13 (noting that OncorMed,
Genetics & IVF Institute and Myriad have begun marketing tests for the BRCA
genes and other community and academic laboratories are introducing their own tests
for genetic disorders to assess future disease risk).
66. See Lori Andrews, Body Science: As Medical Research Unlocks the Secrets of
Genetics, the Battle Over Who Can Have Access to your Personal Life Story is Just
Getting Under Way in Courts and Legislatures, 83 ABA JOURNAL 44, 45 (1997) ("Peo-
ple are starting to use genetic information to measure the consequences of major life
decisions.").
67. See Johnathon M. Lancaster et al., An Inevitable Dilemma: Prenatal Testing for
mutations in the BRCA1 Breast-Ovarian Cancer Susceptibility Gene, 87 OBSTETRICS &
GYNECOLOGY 306, 306 (1996).
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II. Genetics and the Law
A. Legislation Affecting the Dissemination
of Genetic Information
Legislation addressing the use of genetic information is inade-
quate to deal with the recent advances in biotechnology. Several
laws attempt to protect individuals from discrimination based on
their genetic make-up, but the rights of the family to a close rela-
tive's genetic information largely are left untouched. Some argue
that the absence of regulation is appropriate and that medical eth-
ics issues are best dealt with by means other than legislation.68
However, laws intended to prevent discrimination directly affect
the physicians' duty to warn their patients' children of genetic dis-
ease. When disclosure of genetic information no longer threatens
to subject its patients to discrimination by insurers and employers,
a physician will sooner be required to share it with patients'
children.
1. Federal Legislation
Congress has attempted to protect those who have undergone
genetic testing from discrimination by both insurers and employers.
The Health Insurance Portability and Accountability Act of 199669
("HIPAA") prohibits group health insurance plans from determin-
ing clients' eligibility and preexisting conditions based on genetic
information.7" HIPAA, however, does not protect those who must
purchase individual insurance policies71 and does not prohibit in-
68. See DWORKIN, supra note 12, at 12.
Legislators are not oracles. They have no more ability to predict scientific
and technological developments than anybody else .... Those limitations
also raise questions about the desirability of prospective lawmaking. While
preventing harm is more attractive than cleaning up after harm has occurred,
the inability to foretell the future or to envision every possible scenario sug-
gests that advance solutions may turn out to be unwise or even counter-
productive.
Id.
69. Pub. L. No. 104-191, 5701, 110 Stat. 1936 (1996) (as codified at 29 U.S.C.A.
§ 1181 (Supp. 1998)).
70. HIPAA also prohibits insurers from finding preexisting conditions from ge-
netic information "in the absence of a diagnosis of the condition related to such infor-
mation." Id.
71. See id.
(a) Limitation on preexisting condition exclusion period; crediting for peri-
ods of previous coverage ... a group health plan, and a health insurance
officer offering group health insurance coverage, may, with respect to a par-
ticipant or beneficiary, impose a preexisting condition exclusion only if-(1)
such exclusion related to a condition.., for which medical advice, diagnosis,
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surers from requiring prospective clients to undergo genetic testing
or disclose past test results. Under these circumstances, it would
be difficult to prove that insurers used the information to discrimi-
nate against clients. 72 In addition, insurers still may increase policy
rates and even deny coverage of specified procedures and treat-
ments, such as prophylactic mastectomies or oophorectomies.73
Federal law addresses employment discrimination with the
Americans with Disabilities Act ("ADA"). 74 The ADA prohibits
employers from denying employment on the basis of an individ-
ual's disability,75 and requires that employers provide reasonable
accommodations in the workplace for those employees. 76 The criti-
cal question is whether a predisposition to disease, or the diagnosis
of a condition without accompanying symptoms, constitutes a disa-
bility under the ADA. This issue currently is dividing the courts,77
and until the United States Supreme Court rules on it, the ADA
may not adequately protect individuals susceptible to genetic dis-
ease from employment discrimination.
care, or treatment was recommended or received within the 6 month period
ending on the enrollment date ... (B) ... [g]enetic information shall not be
treated as a condition described in subsection (a)(1) of this section in the
absence of a diagnosis of the condition related to such information.
Id.
72. See id.; see also Karen H. Rothenberg, Breast Cancer, The Genetic "Quick
Fix," And The Jewish Community: Ethical, Legal, and Social Challenges, 7 HEALTH
MATRIX 97, 112 (1997) (noting the inadequacies of the Act to protect individuals).
73. See Rothenberg, supra note 71, at 112 ("Nor does it prevent a plan from in-
creasing rates, excluding all coverage for a particular condition, or imposing lifetime
caps on all benefits or on specific benefits . . . Absent other contractual and legal
protections, plans could specifically exclude, for example, prophylactic surgery.").
74. See 42 U.S.C.A. §§ 12101 et seq.
75. See 42 U.S.C.A. § 12112(a) ("No covered entity shall discriminate against a
qualified individual with a disability because of the disability of such individual in
regard to job application processes, the hiring, advancement, or discharge of employ-
ees, employee compensation, job training, and other terms .... "). See also Mark A.
Rothstein, Genetic Discrimination in Employment and the Americans with Disabilities
Act, 29 Hous. L. REV. 23, 52-68 (1992) (noting that the Act limits an employer's pre-
employment inquiries to an applicant's ability to perform work-related duties).
76. See 42 U.S.C.A. § 12112(b)(5). See Abbott v. Bragdon, 107 F.3d 934 (1st Cir.
1997) (holding that HIV-positive status comprises physical impairment under the
ADA), cert. granted, 118 S. Ct. 554 (Nov. 26, 1997).
77. Compare Reichle v. Walsh Offshore, Inc., 1997 WL 728104 (E.D. La. Nov. 20,
1997) (refusing to find HIV-positive employee terminated from job for unexcused
absence physically impaired within definition of the ADA where no symptoms exhib-
ited) with Hernandez v. Prudential Ins. Co. of America, 977 F.Supp. 1160 (M.D. Fla.
1997) (holding that HIV-positive employee had physical impairment that substantially
limited major life activities of reproduction and caring for himself, and was disabled
within the meaning of the ADA).
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2. State Legislation
Roughly half of the states have enacted legislation designed to
protect the privacy of genetic information and to deter discrimina-
tion based on such information.7" Many states, for example, have
legislation which combines protection against discrimination with
protection for the genetic privacy of both individuals and their fam-
ilies. 79 While these statutes are helpful, the range of their protec-
tion is restricted by the Employee Retirement Income Security Act
("ERISA").8 0  By exempting insurance policies provided by em-
ployers from the reach of state regulation, ERISA keeps more than
one-third of the non-elderly insured out of the reach of state anti-
discrimination and genetic privacy laws.8 ' Therefore, despite the
efforts of states to address the important issues generated by ad-
vances in genetic technology, ERISA prevents states from provid-
ing universal protection to their citizens.
3. Proposed Federal Legislation
Legislators recently have introduced several bills in Congress
that protect individuals from discrimination based on genetic infor-
mation and ensure that genetic information is kept private. 2 Only
78. See Robert Pear, States Pass Laws to Regulate Uses of Genetic Testing, N.Y.
TIMEs, Oct. 18, 1997, at Al ("Concerned that the Federal Government is acting too
slowly to protect the confidentiality of genetic information, states are passing their
own laws to regulate the use of genetic test results to prevent discrimination by insur-
ers and employers .... At least 26 states have adopted such laws.").
79. CAL. INS. CODE §10146 (West 1997) (requiring strict confidentiality of genetic
information and establishing standards regarding unfair discrimination based on ge-
netic information); C.R.S.A. § 10-3-1104.7 (1)(c) (1997) ("To protect individual pri-
vacy and to preserve individual autonomy with regard to the individual's genetic
information, it is appropriate to limit the use and availability of genetic informa-
tion."); GA. ST. § 33-54-1 (1997) (limiting use and availability of genetic information
to prevent insurance companies from denying access on basis of genetic information);
N.J.S.A. § 10:5-44 (1997) (requiring individual authorization to collect, retain, or dis-
close genetic information).
80. 29 U.S.C.A. §§ 1001-1461 (1988).
81. See Rothenberg, supra note 71, at 109-10 (noting that ERISA exempts self-
funded plans from state insurance laws and that more people will be affected by this
exemption as more employers are likely to turn to self-funded plans in the future).
82. See, e.g., The Genetic Privacy and Nondiscrimination Act of 1997, H.R. 2198,
105th Cong. (enacted). The proposed act would give the individual undergoing ge-
netic testing the authority to determine who may collect and analyze his DNA, and
for what purposes the analysis is to be completed. See id. He may refuse to permit
his DNA to be used for research or commercial activities, may inspect and obtain
records of the test results, may order the destruction of the DNA, and also may dele-
gate another person to order the destruction of the DNA in the event the tested indi-
vidual dies. See id. Anyone providing a genetic test would be required to provide
specific information to the individual undergoing testing before performing the DNA
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one bill, however, specifically addresses family members' access to
genetic information, in addition to the access of insurers and em-
ployers.83 The Medical Privacy in the Age of Technologies Act of
1997 permits health care providers to furnish an inpatient's next of
kin or individual representative with protected health information,
including genetic test results unless the patient objects to such dis-
closure.14 Therefore, physicians would be allowed to notify a pa-
tient's family of genetic disease absent an explicit demand from the
patient that such information be kept confidential. While this leg-
islation would permit, and not require, a physician to disclose ge-
netic information to a patient's children without her consent, it
places the burden on the patient to deny disclosure of the informa-
tion to her children if she wishes to protect her own privacy.85
B. The Physician-Patient Relationship and Confidentiality
An ancient principle requires that physicians keep confidential
information they learn about a patient during treatment.86 The ra-
tionale behind this tenet is to protect the privacy of the patient, and
to encourage candid sharing of personal information so that the
physician may render an accurate diagnosis and effect appropriate
treatments.87 Without an assurance that potentially embarrassing
information will be maintained in confidence, those in need of
medical advice or treatment may avoid visiting a health care pro-
vider until the problem is advanced and difficult, or perhaps impos-
collection, obtain written authority to carry out the testing from the individual, and
abide by instructions given regarding maintenance and destruction of the sample. In
addition, the tester would have to restrict access to the genetic information to those
authorized by the individual tested to have it. See id.
83. See Medical Privacy in the Age of New Technology Act of 1997, H.R. 1815,
105th Cong.
[A] health care provider ... may disclose protected health information re-
garding an individual who is an inpatient in a health care facility to the indi-
viduals' next of kin, to an individual representative of the individual.., if (1)
the individual who is the subject of the information (A) has been notified of
the individual's right to object at the time of admission to the facility and has




86. See Buchanan, supra note 8, at 141-42 (reviewing the requirement in medical
codes, starting with the Hippocratic Oath, that physicians are sworn to complete con-
fidentiality); See Paul A. Lombardo, Genetic Confidentiality: What's the Big Secret? 3
U. CHI. L. SCH. ROUNDTABLE 589, 593 (1996) ("This ancient medical principle... has
been included in every physician's oath and code of ethics since Hippocratic times.").
See supra note 2 and accompanying text.
87. See Friedland, supra note 4 at 256.
264
MOTHER KNOWS BEST
sible to treat.88 Therefore, the trust a patient develops in her
health care provider may prove critical for health maintenance.
Although physicians generally are prohibited from disclosing a
patient's medical information without her consent, many excep-
tions to this rule apply. 9 In fact, so many exceptions have been
made that it has been suggested that the concept of physician-pa-
tient confidentiality is a dead letter.9° Without direction from fed-
eral law, health care providers depend on professional standards,
state legislation, and court decisions to determine when they must
disclose medical information without the patient's consent.91
Statutes determining when physicians must maintain or sacrifice
confidentiality vary from state to state. In New York, any health
care provider authorized to practice in the state may not disclose
information obtained in such capacity that is necessary to treat a
patient, unless that individual consents to the disclosure.92 New
York statutes and regulations, however, allow for a number of ex-
ceptions to this requirement of confidentiality. For example, where
88. See Elizabeth B. Cooper, Historical and Analytical Overview of Policy Issues
Affecting Women Living with AIDS: A Blueprint for Learning from Our Past, 72 BUL-
LETIN OF THE NEW YORK ACADEMY OF MEDICINE 283, 290 (1995) (emphasizing the
importance of confidentiality in the context of testing for HIV [the virus that causes
AIDS] "women, like men, may choose not to know their serostatus because of the
many extant barriers to testing, including ongoing fears of breaches of confidentiality,
insufficient access to care and services for those who test positive, and continuing
discrimination against people (and families) with HIV").
89. See Buchanan, supra note 8, at 142.
There are occasions. . . when a physician must determine whether or not his
duty to society requires him to take definite action to protect a healthy indi-
vidual from becoming infected because a physician has knowledge, obtained
through the confidences entrusted to him as a physician, of other communi-
cable disease to which tothe healthy individual is about to be exposed.
See id.
90. See Lombardo, supra note 86, at 593 ("Medical confidentiality, as it has tradi-
tionally been understood by patients and doctors, no longer exists. This ancient medi-
cal principle, which has been included in every physician's oath and code of ethics
since Hippocratic times, has become old, worn-out, and useless; it is a decrepit con-
cept.") (footnote omitted). Because medical information is so easily accessible
through computer networks and from insurance providers, confidentiality of medical
records is significantly diminished. See David Orenlicher, Genetic Privacy in the Pa-
tient-Physician Relationship, in Genetic Secrets 85-86 (Mark A. Rothstein ed., 1997).
91. See Friedland, supra note 4, at 253-54.
92. See N.Y. C.P.L.R § 4504(a) (McKinney 1992 & Supp. 1998).
Unless the patient waives the privilege, a person authorized to practice
medicine, registered professional nursing, licensed practical nursing, den-
tistry, podiatry or chiropractic shall not be allowed to disclose any informa-
tion which he acquired in attending a patient in a professional capacity, and
which was necessary to enable him to act in that capacity.
See id.
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patients are diagnosed with communicable diseases,93 sexually
transmitted diseases, 94 and AIDS, 95 they are considered threats to
the public or community, and thus health care providers must no-
tify the Department of Health to prevent harm to third parties.9 6
As opposed to victims of communicable diseases, a patient with
genetic disease may not create a risk for the public at large, but
may pass on mutant genes to children who could benefit from ge-
netic information. 97 For this reason, some argue that another ex-
ception to the physician-patient confidential relationship should
apply in the context of genetic information. The privacy of genetic
information is often analogized to the privacy of one's HIV status
because of the potential for stigma and discrimination that is cre-
ated when an individual is identified as infected or diseased. 98
In New York, legislators have made great efforts to afford pri-
vacy to those undergoing HIV testing.99 When a person tests posi-
tive for HIV, however, the law permits a physician to encourage
the patient to notify his or her partners of their risk of contracting
HIV.a00 If the patient refuses to do so, the physician has the discre-
93. See N.Y. PUB. HEALTH LAw § 2101 (McKinney 1993); N.Y. COMP. CODES R
& REGS. tit. 10, § 2.10 (1997).
94. See N.Y. PUB. HEALTH LAW sec. 2300 (McKinney 1993); N.Y. COMP. CODES
R. & REGS. tit. 10, § 23.3 (1997).
95. See N.Y. PUB. HEALTH LAW sec. 2782 (McKinney 1993 & Supp. 1998); N.Y.
COMP. CODES R. & REGS. tit. 10, § 24-1.2 (1997).
96. See N.Y. PUB. HEALTH LAW § 2101 (1) (McKinney 1993) ("Every physician
shall immediately give notice of every case of communicable disease required by the
department to be reported to it, to the health officer of the local health district where
such disease occurs.").
97. In order to establish the physician-patient privilege, three elements are essen-
tial: the existence of a doctor and patient relationship, the information at issue must
be obtained in' the course of treatment, and the information must be necessary for
treatment. As discussed in Part II.C, where family members are the beneficiaries of
genetic information, courts have construed the physician-patient relationship as ex-
tending to these individuals. See Vincent C. Alexander, Supplementary Practice Com-
mentaries, N.Y. C.P.L.R. § 4504(a) (McKinney 1993 & Supp. 1998); See infra Part
II.C.
98. See Scott Burris & Lawrence 0. Gostin, Genetic Screening from a Public
Health Perspective: Some Lessons from the HIV Experience, in GENETIC SECRETS 137,
148-49 (Mark A. Rothstein ed., 1997); see also Cooper, supra note 87 and accompa-
nying text.
99. See N.Y. PUB. HEALTH LAw § 2785(2) (McKinney 1993 & Supp. 1997).
100. See N.Y. PUB. HEALTH LAw § 2782(4)(a) (McKinney 1993 & Supp. 1998).
A physician may disclose confidential HIV related information under the
following conditions: (1) the disclosure is made to a contact or to a public
health officer for the purpose of making the disclosure to said contact; and
(2) the physician reasonably believes disclosure is medically appropriate and
there is a significant risk of infection to the contact; and (3) the physician has
counseled the protected individual regarding the need to notify the contact,
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tion to notify the person at risk or may arrange for a state health
official to notify the patient's partner, even without the patient's
consent. 10 1 With the advent of drug therapies shown to retard the
progression of AIDS in people living with HIV, the public has be-
come more receptive to a new exception to physician-patient confi-
dentiality in these circumstances.10 2 Apparently, where preventive
measures are available to those who may be at risk for disease, the
public is better able to accept breaches in the confidential
relationship. °3
C. Conflict in the Courts
Courts have recognized an exception to the physician-patient
privilege when revealing confidential medical information prevents
foreseeable harm to identifiable third parties." 4 Courts also have
and the physician reasonably believes the protected individual will not in-
form the contact; and (4) the physician has informed the protected individ-
ual of his or her intent to make such disclosure to a contact and has given the
protected individual the opportunity to express a preference as to whether
disclosure should be made by the physician directly or to a public health
officer for the purpose of said disclosure. If the protected individual ex-
presses a preference for disclosure by a public health officer or by the physi-
cian, the physician shall honor such preference.
Id.
101. See id.
102. Exceptions to physician-patient confidentiality have been made where patients
with infectious conditions, such as HIV, threaten the health of third parties, and coun-
seling and treatment may benefit them. See AIDS: More Reporting of Virus En-
couraged, AMERICAN POLITICAL NETWORK-HEALTH LINE, Aug. 21, 1997, at 13.
Until recently, there was a belief that patient privacy was necessary to en-
courage 'voluntary testing and counseling to help slow the spread of infec-
tion.' Now, however, 'new drug therapies make early detection and
treatment more important,' and 'strong legal protections against discrimina-
tion have eased some of the pressure for confidentiality.'
Id.; Lawrence 0. Gostin et al., The Public Health Information Infrastructure: A Na-
tional Review of the Law on Health Information Privacy, 275 JAMA 1921 (1996) (dis-
cussing provisions in the law for disclosure of confidential medical information or
partner notification where therapeutic measures are available to third parties at risk
of infection).
103. See Lynda Richardson, U.S. Urging Identification of Patients with HIV, N.Y.
TIMES, Oct. 21, 1997, at B5 ("Many advocacy groups have softened their opposition to
HIV reporting in recent months because of medical advances."); <http://www.
abcnews.com:80/sections/newsuse/hiv9lO/index.html> (noting that "mandatory [HIV]
reporting has grown less controversial in recent years, especially with the advent of
treatments for people who are infected but not yet sick").
104. See Tarasoff v. Regents of University of California, 551 P.2d 334 (Cal. 1976)
(en banc) (special relationship between physician and patient supports duty of reason-
able care to protect identifiable third party from harm threatened by patient); see also
Bradshaw v. Daniel, 854 S.W.2d 865 (1993) (holding that physician had duty to warn
patient's wife of her risk of contracting Rocky Mountain Spotted Fever when he
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determined that psychotherapists, who, while treating patients,
learn that the patient is likely to attack or cause serious harm to a
third party, have a duty to warn that endangered individual and
even take steps to protect that third party from the risk that was
revealed through confidential therapy sessions. °5 Moreover,
courts have created new exceptions to the confidential physician-
patient relationship that cover dangers ranging from acts of vio-
lence to exposure to contagious disease.10 6 Courts have split, how-
ever, on whether to carve out another exception where genetic
information may help a patient's family avoid harm.1 0 7
In Pate v. Threlkel,a08 the Florida Supreme Court decided
whether physicians caring for a woman diagnosed with medullary
thyroid carcinoma owed her a duty to warn that her condition was
genetically transferable. 1 9 One factor complicating the case was
that the plaintiff was the patient's daughter, Heidi Pate. Only after
learning that she also suffered from medullary thyroid carcinoma
did Pate learn that she inherited the disease from her mother.
Holding that the physicians had a duty to warn of the cancer's ge-
netic nature, the court ruled that Pate satisfied the privity require-
should have known patient had such disease); Hoffmann v. Blackmon, 241 So.2d 752
(Fla. Dist. Ct. App. 1970) (finding physician negligent for failing to diagnose tubercu-
losis in father, and failing to warn family of child's risk of contracting such disease).
105. See Tarasoff, 551 P.2d at 345 (requiring that a therapist who "reasonably
should have determined, that a patient poses a serious danger of violence to others, [ ]
bears a duty to exercise reasonable care to protect the foreseeable victim of that
danger").
106. See supra note 103.
107. Compare Pate v. Threlkel, 661 So.2d 278 (1995) (holding that physician's duty
to warn patient's family members of genetic disease satisfied by notifying only pa-
tient) with Safer v. Pack, 677 A.D. 1188 (N.J.Super. 1996) (rejecting satisfaction of
duty to warn with patient notification, but instead requiring that physicians take rea-
sonable steps to ensure that family members are notified of genetic disease).
108. 661 So.2d 278 (1995). Heidi Pate, the adult daughter of a woman diagnosed
with medullary thyroid carcinoma, a genetically transferable cancer, filed a complaint
against her mother's physicians for failure to warn of the genetic nature of the cancer.
Undergoing treatment for her own case of medullary thyroid carcinoma, Pate claimed
that the doctors should have been aware of the disease's hereditary character and that
given early warning, she could have been closely monitored for the cancer, and could
have taken precautionary measures to prevent its onset. The trial court dismissed
Pate's complaint for lack of privity with her mother's physicians and the District
Court affirmed. Recognizing that in previous cases, intended beneficiaries of the pre-
vailing standards of care were permitted to bring a cause of action against a profes-
sional despite a lack of privity, the Florida Supreme Court decided that the more
tenuous relationship between plaintiff and defendant in this case did not foreclose
liability.
109. See 661 So.2d at 281 (determining that health care providers were under a duty
to warn Mrs. New of the importance that her children undergo genetic testing to iden-
tify their predisposition to same disease).
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ment because she could be considered the intended beneficiary of
the duty."10 The Pate court, however, specifically noted that the
physician's duty to warn would be satisfied by notifying only the
patient (who could be expected to share the information with her
children) and expressly rejected the requirement that the physician
inform the patient's children directly."'
In Safer v. Pack,"2 a New Jersey Superior Court reached a differ-
ent conclusion when faced with a similar case and held that a physi-
cian's duty to warn is not satisfied by informing the patient; rather,
reasonable steps must be taken to assure that the information
reaches the parties at risk."' The Safer court emphasized that indi-
viduals can begin any treatments or changes in lifestyle necessary
to prevent the onset of the disease as soon as they learn that they
have a greater risk of developing it." 4 The court also noted that in
the case of genetic disease, the duty to warn of avertible risk is
110. Id. at 282 (expanding requirement in past courts that privity exist between
plaintiff end physician to maintain cause of action to third party beneficiaries of
relationship).
Here, the alleged prevailing standard of care was obviously developed for
the benefit of the patient's children as well as the patient. We conclude that
when the prevailing standard of care creates a duty that is obviously for the
benefit of certain identified third parties, then the physician's duty runs to
those third parties.
Id.
111. Id. at 282.
To require the physician to seek out and warn various members of the pa-
tient's family would place too heavy a burden upon the physician. Thus, we
emphasize that in any circumstances in which the physician has a duty to
warn of a genetically transferable disease, that duty will be satisfied by warn-
ing the patient.
Id.
112. 677 A.2d 1188 (N.J. Super. 1996). Donna Safer, whose father was treated for
and died of colon cancer during the 1960s, sued the estate of her father's physician for
failure to warn of the genetic nature of the condition which led to her father's fatal
disease. At the time of the suit, Safer had been diagnosed with multiple polyposis and
colon cancer, which had metastasized to her liver. Multiple polyposis is'an inherited
condition that, if left untreated, leads to colorectal cancer. Because she was a child at
the time of her father's illness, Safer only learned that he suffered from the same
disease after she reviewed his medical records. The trial court dismissed Safer's case
because it required that either a patient-physician relationship exist or that a threat to
the public health or community at large exist in order to bring a cause of action in this
situation. The New Jersey Superior Court permitted Safer's claim against the physi-
cian's estate.
113. See id. at 1192 ("We decline to hold ... that, in all circumstances, the duty to
warn will be satisfied by informing the patient.").
114. Id. ("The individual or group at risk is easily identified, and substantial future
harm may be averted or minimized by a timely and effective warning.").
1999] 269
FORDHAM URBAN LAW JOURNAL [Vol. XXVI
narrow enough to serve the interests of justice.115 The court, in
Safer, did not define what "reasonable steps" were, however, leav-
ing open the question of how the confidentiality between doctor
and patient should be limited in certain circumstances.1 1 6
III. Aligning Legal Policy with the Current Status
of Biotechnology
Although courts have long encountered breaches of confidential-
ity for the benefit of at-risk third parties, disclosure of genetic in-
formation regarding predisposition to cancer is a new issue to
legislators and judges alike. Because developments in genetics are
far outpacing the legal system, it is necessary to update the law to
manage current conflicts and also anticipate the issues that will ac-
company future advances. This Part evaluates the rationales em-
ployed by the Pate and Safer courts, suggests other elements that
courts should consider, and proposes a balancing test that will de-
termine where disclosure of genetic information is appropriate.
A. Pate and Safer Reconsidered
The courts in Pate v. Threlkel and Safer v. Pack reached dispa-
rate conclusions because of several significant factors. For exam-
ple, when physicians diagnosed Heidi Pate's mother with
medullary thyroid carcinoma, a genetically transferable disease,
Pate was an adult who would have been able to decide for herself
how to use the information 'that she was at risk.' 7 Donna Safer,
however, was a minor at the time her father suffered from colon
cancer, and discovered his condition only by researching his medi-
cal records after she was diagnosed with cancer. 1 8
The Pate court determined that, given the, knowledge that her
condition was genetically transmissible, Pate's mother likely would
115. Id. ("Although an overly broad and general application of the physician's duty
to warn might lead to confusion, conflict or unfairness in many types of circumstances,
we are confident that the duty to warn of avertible risk from genetic causes, by defini-
tion a matter of familial concern, is sufficiently narrow to serve the interests of
justice.").
116. Id.
We need not decide, in the present posture of this case, how, precisely, that
duty is to be discharged, especially with respect to young children who may
be at risk, except to require that reasonable steps be taken to assure that the
information reaches those likely to be affected or is made available for their
benefit.
Id.
117. See Pate v. Threlkel, 661 So.2d at 279.
118. See Safer v. Pack, 677 A.2d at 1189.
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have passed this information on to her adult daughter. 119 In Safer,
however, notifying the plaintiff would have been much more com-
plicated, and probably best left until she became an adult.120 The
Safer court thus held that additional measures should have been
taken to assure that Safer eventually was informed about her fa-
ther's condition.1 21 Accordingly, where complicating factors exist
with respect to sharing genetic information with family members
(e.g., where such family members are minor children), courts may
require additional support from health care professionals to ensure
that the situation is handled appropriately.
The nature of the relationship between the physician and the
family may be another important distinction for the courts. For
example, Donna Safer's mother also was treated by the defendant
physician who should have disclosed the genetic nature of her hus-
band's cancer because she specifically asked about the risk to her
family.1 22 Heidi Pate, on the other hand, established no relation-
ship with her mother's physicians, and requiring the doctors to seek
out and share the genetic information with the patient's children
would have been too great a burden. 2 3
Moreover, the plaintiffs' parents were diagnosed with signifi-
cantly different conditions. While the type of cancer from which
Pate's mother suffered has no preliminary warning signals, 24
Safer's father had multiple polyposis, a genetically linked condition
that later develops into colon cancer. 15 The knowledge of her fa-
ther's condition would have alerted Safer to monitor closely for
polyposis and to undergo the available treatment to avert the onset
of colon cancer. The Safer court's decision likely Was influenced by
the fact that such information would have proven extremely useful
to the plaintiff, and therefore it held that the treating physicians
119. See Pate, 661 So.2d at 282 ("Our holding should not be read to require the
physician to warn the patient's children of the disease ... the patient ordinarily can be
expected to pass on the warning.").
120. See supra note 115 and accompanying text.
121. See id.
122. See Safer, 677 A.2d at 1190. Safer's mother claims that the physician reassured
her that her husband was being treated for a condition that would not harm the chil-
dren. See id.
123. See supra note 110 and accompanying text.
124. See Pate, 661 So.2d at 279 (noting that Pate's discovery of her condition oc-
curred only after the cancer had reached an advanced stage).
125. See Safer, 677 A.2d at 1190 ("[M]ultiple polyposis is a hereditary condition
that, if left undiscovered and untreated, invariably leads to metastatic colorectal
cancer.").
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were obligated to take the necessary steps to provide the plaintiff
with the information.
Although Heidi Pate's disease was not preceded by a "warning"
stage, such as polyposis, she also would have benefitted tremen-
dously from a warning from her mother's physicians, because med-
ullary thyroid carcinoma may effectively be prevented. 126 Without
a precancerous condition like polyposis, however, which would sig-
nal the need to take appropriate preventive measures, the Pate
court may not have believed that breaking physician-patient confi-
dentiality could have prevented Pate's cancer.
Both the Pate and Safer courts failed to consider several impor-
tant factors that likely will prove critical to future cases. When
testing for genes that indicate a predisposition to disease, courts
should consider the accuracy of the test performed and the ability
of the physician to interpret its results. A test that cannot provide
accurate results with reasonable certainty does not provide physi-
cians with information that will enable patients to make appropri-
ate decisions with respect to their physical and emotional well-
being.127 Even where genetic tests provide accurate results, to
render beneficial counseling to their patients, physicians must ade-
quately be educated about the significance of test results and how
to interpret them (training which currently is lacking in primary
care providers). 28
The likelihood of gene transmission to the next generation and
the severity of the corresponding condition also must be consid-
ered. Finally, the potential for discrimination against and stigmati-
zation of the patient must be carefully restricted.
B. A Balancing Test
Future cases involving the duty to disclose genetic information
should be decided by using a balancing test. Where advances in
technology and legislation occur so rapidly, a bright-line rule will
not be effective for long. The weight attributed to the elements on
either side of this test will shift as scientists advance genetic tech-
nology, legislators further protect the privacy of genetic informa-
126. See Leslie M. Alexandre, Genetic Testing for Cancer Susceptibility: What Your
Institution Needs to Know (visited Feb. 11, 1998) <http://www.medscape.com/ACCC/
Onclssues/1997/v12.nO2/oi1202.02.alexandre.html> ("[A] positive [gene] test for muta-
tions in the RET gene is a virtual guarantee of developing medullary thyroid carci-
noma, and prophylactic surgery is 100 percent effective in preventing this frequently
fatal form of thyroid cancer.").
127. See infra note 139 and accompanying text.
128. See infra note 142 and accompanying text.
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tion, and physicians and the public learn more about genetic
testing. Thus, the five factors in this proposed balancing test will
have varying levels of significance and will allow for different re-
sults when applied to newly discovered mutations linked to
diseases.
The following factors will best determine when to permit an ex-
ception to physician-patient confidentiality because they will allow
courts to adapt to current technological advances and legislation.
Courts should weigh:
(1) the severity of the disease identified by testing;
(2) the availability of preventive or curative options for that
disease;
(3) the accuracy and reliability of the test performed;
(4) the ability of the physician or health care provider to inter-
pret and address issues relevant to the test performed; and lastly,
(5) the protections afforded to the tested individual against
discrimination.
C. Applying the Balancing Test to the BRCA Gene Mutations
Although a carrier of genetic mutations diagnosed with breast or
ovarian cancer is likely to inform her children that they also may
be at increased risk of cancer if they also carry the mutations, cur-
rently there is no legal duty to share this information with family
members.1 2 9 Also, the patient may have her own reasons for keep-
ing it confidential. Therefore, the application of the balancing test
in the context of the BRCA mutations will provide a useful tool for
physicians and courts in determining whether there is a duty to
warn a patient's children.
1. Severity of Disease
The severity of the disease or condition to which an individual
may be predisposed by inherited genetic mutations is a necessary
consideration because breach of confidentiality is a measure of last
resort, and can be justified only if the threatened harm is imminent
or serious.130 A genetic mutation increasing an individual's risk for
129. See Friedland, supra note 4, at 271 ("[E]ven though genetic defects may pose a
threat of serious harm to others, the common law has never required an individual to
come to the aid of another when the other's situation is not that of the individual's
making.").
130. See Lori B. Andrews, Gen-Etiquette: Genetic Information, Family Relation-
ships, and Adoption, in GENETIC SECRETS 255, 269 (Mark A. Rothstein ed., 1997)
(noting that the National Research Council's Commission for the Study of Inborn
Errors of Metabolism, the President's Committee on Ethical Issues in Medicine, and
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male pattern baldness must be treated differently than one indicat-
ing susceptibility to an untreatable form of cancer. Coping with
the alterations in self-image that balding may create is less serious
than battling a life-threatening disease such as cancer. Statutes and
cases support measures other than unauthorized disclosure of a pa-
tient's medical information to a third party, unless the disclosure is
necessary to avert the threat of substantial harm.131 Therefore, in
applying the proposed balancing test, the more serious the condi-
tion, the more heavily it will weigh against maintaining
confidentiality.
For example, breast and ovarian cancer are serious diseases,
ranking among the top five causes of death in American women,
and are difficult to eradicate if not detected in an early stage of
development.132 Therefore, the application of the severity element
related to the BRCA mutations weighs heavily in favor of disclos-
ing this genetic information.
2. Availability of Preventive or Curative Options
The second element to consider is the availability of effective
preventive or curative measures. Knowing that one is subject to an
increased risk of developing serious disease may create significant
emotional distress, especially if there are no available means of
treating or averting the onset of disease. Although some argue that
the mere notification that one is at increased risk may provide
some benefit, 33 if the available options are limited to "heroic" or
the Institute of Medicine's Committee on Assessing Genetic Risks all recommend
limiting disclosure of genetic information to cases of life-threatening, massively disa-
bling, irreversible or fatal conditions).
131. See id. at 269; DiMarco v. Lynch Homes, 583 A.2d 422 (Pa. 1990) (holding that
a physician has a duty to teach safe sex practices to patient with hepatitis in lieu of
warning sex partners).
132. The serious nature of breast and ovarian cancer, coupled with more effective
treatment with early detection weigh in favor of notifying children of their mother's
BRCA carrier status. See Safer v. Pack, 677 A.2d 1188, 1192 (1996) ("The individual
or group at risk is easily identified, and substantial future harm may be averted or
minimized by a timely and effective warning."); see also John Bell, Prenatal Diagnosis:
current status and future trends, in HUMAN GENETIC INFORMATION: SCIENCE, LAW
AND ETHICS 25 (noting that "screening early in life ... would permit individuals at
high risk to modify their life styles so that they would be exposed to fewer environ-
mental risk factors than otherwise"); but c.f Daniela Altimari, 400 Women Attend
Forum on Breast Cancer, HARTFORD COURANT, Sept. 26, 1997, at B1 (Bella Abzug
argues that genetic testing deflects attention from environmental factors).
133. See Groopman, supra note 45, at 46 (noting that [the awareness of one's pre-
disposition to disease] "led many people to take better care of themselves-stop
smoking, end drug use, improve diet, take up exercise, seek stress reduction... [and]
the knowledge that one ... was mortal gave many young people a precocious sense of
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drastic measures, this factor will weigh in favor of maintaining con-
fidentiality. However, if researchers discover curative procedures
(such as gene therapy or drug treatment) or determine that avoid-
ance of exposure to specific external factors will effectively thwart
the onset of disease, then this element will weigh in favor of disclo-
sure to offspring.
Currently, there is no generally accepted method that has been
proven to prevent breast or ovarian cancer,3 although close sur-
veillance 135 and measures such as drug therapy, prophylactic mas-
tectomy and oophorectomy promise significantly to reduce the
risk. 36 The removal of the breasts and ovaries may seem like an
extreme preventive procedure, but actually may serve to substan-
tially eliminate emotional distress and anxiety.137 Many women,
however, may eliminate either procedure as a viable option be-
cause they hope to have children or decide that surgery is too
drastic.
Once identified as a BRCA mutation carrier, an individual's de-
cision about how best to avoid cancer surely is excruciating and
very personal. Although the disclosure of genetic information
would allow a carrier's children to engage in their own decision
making processes, the limited options presently available weigh
against disclosure.
maturity and wisdom"); Alexandre, supra note 126 ("[W]hen scientific discoveries
venture into promising but uncertain new realms, some people understandably react
with caution. Although such apprehension can be constructive and can lead to fur-
ther education and knowledge, the reaction can be harmful when it discourages peo-
ple from seeking a potentially life-saving approach to health care."). It is interesting
to note that the author of this article, Leslie Alexandre, is Vice President of Corpo-
rate Affairs.at OncorMed, one of the biotechnology companies currently marketing
genetic testing kits.
134. See Wendy C. McKinnon et al., Predisposition genetic testing for late-onset dis-
orders in adults: a position paper of the National Society of Genetic Counselors, 278
JAMA 1217 (1997) ("For many late-onset disorders, such as cancer, much uncertainty
surrounds the molecular biology of predisposition genetic testing. Likewise, there is a
dearth of data regarding appropriate medical management for gene mutation carriers
and the psychological aspects of testing.").
135. See Singer & Cebul, supra note 51, at 178 ("Although many women may be
reluctant to participate [in mammographic screenings] due to cancer anxiety, compli-
ance is generally improved when the patient is aware of the risk.").
136. See id. at 179 (naming prophylactic mastectomy as the only established pre-
ventive option currently available, but warning that cases of breast cancer have oc-
curred in women after having their breasts removed and that no studies of the
procedure's efficacy have been conducted yet).
137. See Groopman, supra note 45, at 46 (relating a patient's difficult decision to
have her breasts and ovaries removed to reduce the anxiety felt by both her family
and herself).
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3. Accuracy and Reliability of Test
If the genetic test performed on an individual cannot be relied
upon to provide accurate results, then such information threatens
to bring more harm than benefit. Tests which produce false nega-
tive results likely will relieve anxiety and create a false sense of
security in individuals who actually are at increased risk for dis-
ease. A mistaken belief that they are free of the specific genetic
mutation may deter these individuals from obtaining the surveil-
lance or treatment that may save their lives. 138 On the other hand,
false positive results are sure to create significant emotional dis-
tress in persons whose risk for disease is no greater than those in
the general population. Therefore, where genetic conditions can-
not be identified with accuracy, genetic information should be kept
confidential.
Today, there is no test available that has been proven to be accu-
rate in identifying risk-predicting BRCA mutations. 139 Because
numerous mutations of the BRCA1 and BRCA2 genes exist, and
researchers have not determined which mutations correlate with
manifestation of disease, it is quite possible that an individual iden-
tified as a BRCA mutation carrier may actually carry a mutation
that does not contribute to the onset of cancer.140 Until these tests
138. See Rothenberg, supra note 71, at 103 (fearing that "genetic determinism,"
where an individual believes her future is defined and predicted by genetic makeup
and cannot be changed, will result from genetic testing).
139. See Malinowski & Blatt, supra note 15, at 1243 ("The predictive capability of
many genetic tests remains scientifically undefined for the general population.").
140. See Cunningham, supra note 63, at 34.
[E]ven after correctly detecting the presence of a mutation, there is only a
probabilistic likelihood of the actual expression of malignancy. In screening
terminology, this could be called a false screening positive for the women
who have a mutation but are spared by failure of expression, or who have
mutations which do not lead to an increased risk of cancer.
Id.; Singer & Cebul, supra note 51, at 175-76 (noting that there are no published data
reporting the accuracy of tests for BRCA1 mutations, and that because mutations
may be difficult to detect, false negatives could result from testing); See Ruth Hub-
bard & R.C. Lewontin, Sounding Board; Pitfalls of Genetic Testing, 334 NEW ENG. J.
MED. 1192, 1192-93 (1996). Because the onset of breast or ovarian cancer depends on
numerous factors, depending on DNA patterns to predict disease is problematic.
Only a few of the several variants of BRCA1 and BRCA2 are associated with tumor
formation. Additionally, even a woman with a family history of cancer who tests posi-
tive for one of the mutations may never develop cancer. At present, biotechnology
companies that sell tests for the BRCA1 mutation are not required to involve the
Food and Drug Administration, and thus there has been no external certification of
the tests' quality or the interpretation of their results. See also Heather Bryant, Ge-




have been shown to identify predisposition for cancer with suffi-
cient accuracy, this factor will weigh against disclosure.
4. Education and Training of Physicians
To render genetic testing beneficial for patients, physicians must
have the ability to interpret test results and understand their signif-
icance and meaning. Because test results often are not clear, physi-
cians delivering the results should be educated about the
identification of gene mutations, as well as their significance. Crit-
ics of genetic testing in the clinical environment warn that few pri-
mary providers have been adequately trained to determine what
genetic test results mean, and what information must be provided
to patients undergoing testing.141 Any benefit to the individual be-
ing tested results from the physician's advice and direction. If phy-
sicians themselves have not learned how to interpret and use test
results to promote better health, the patients are not likely to bene-
fit from such information, and thus this element would weigh in
favor of maintaining confidentiality.
While plans to further educate physicians and other health care
providers about genetic testing are underway, 42 the majority of
physicians currently do not possess adequate knowledge or training
to benefit their patients who wish to undergo genetic testing.
143
141. See Malinowski & Blatt, supra note 15, at 1245.
142. See Collins, Preparing Health Professionals, supra note 30 (noting that the Na-
tional Coalition for Health Professional Education in Genetics plans to provide a na-
tional, 'systematic approach to educating health care providers through internet
programs, requiring the inclusion of genetic information on board and licensure ex-
ams, and standardized genetics curricula).
143. See id.
[M]ost health professionals are not prepared to integrate genetics into
clinical practice. A study of DNA-based colon cancer susceptibility testing
revealed that nearly one third of physicians who delivered such test results
did not fully understand their meaning. Surveys also show that many health
professionals have insufficient knowledge of available genetic resources.
Id. Bernadine Healy, Editorial: BRCA Genes-Bookmaking, Fortunetelling, and
Medical Care, 336 NEw ENG. J. MED 1448 (1997) ("It is too early to use BRCA gene
testing in every day clinical practice, because it violates a commonsense rule of
medicine: don't order a test if you lack the facts to know how to interpret the re-
sults."); Malinowski & Blatt, supra note 15, at 1245-46.
[D]ue to the absence of adequate clinical data, health care providers cannot
interpret the results of predictive genetic tests for most of their patients with
any reliability even when they are knowledgeable about genetics. This inter-
pretation problem is exacerbated because the current generation of health
care does not possess such knowledge. Their lack of genetic education and
the novelty of the technology makes providers dependent upon the develop-
ers and manufacturer of these tests ... for information.
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When more physicians can provide their patients with sufficient ex-
planation and counseling with regard to BRCA testing, then disclo-
sure to patients' offspring will be more acceptable. At this time,
however, this element must weigh against such disclosure.
5. Potential for Discrimination and Stigmatization
If genetic testing reveals that an, individual is susceptible to seri-
ous illness, a court must consider the potential that such informa-
tion will be used to deny that person health insurance or
employment. This factor will depend upon the progress made by
legislators to enact laws that protect all individuals against such dis-
crimination. Moreover, without adequate protections against un-
authorized disclosure of genetic information to third parties,
carriers likely will be perceived as "prediseased" or disabled, even
before they manifest any signs of illness.'44 Until firm protections
are in place, this element should weigh against disclosure.
Although some individuals may be protected by state laws
prohibiting discrimination by employers and insurance providers,
no current legislation assures that all who may benefit from BRCA
testing will be protected from discrimination. Therefore, it is im-
proper to suggest that physicians should disclose genetic informa-
tion to family members who then may be denied access to
insurance or employment. The patients themselves are in the best
position to know whether the benefit of disclosure will outweigh
the harm to their children, and should, therefore, decide the appro-
priate time and means to share genetic information with their chil-
dren. Until universal genetic privacy is afforded by federal
legislation, this factor strongly weighs against disclosure by
physicians.
The current status of genetic research, professional education,
and legislation results in the severity of disease as the only factor of
the balancing test that favors disclosure to children of a BRCA mu-
tation carrier. One may argue that breast and ovarian cancer are
so serious that individuals should be aware of an increased risk so
that they can make informed personal choices about their own ge-
netic testing, lifestyle, and health management. However, because
144. See Joyce Wadler, Double Exposure, NEW YORK MAGAZINE, Sept. 18, 1997, at
24, 26 ("I looked after my health and it still didn't matter. I was my own Unabomber,
carrying my future from the time I was born, caught in a genetic accident."). The
author of this article was a breast cancer survivor who described her experience after
being diagnosed with ovarian cancer and learning that she carried genetic mutations
which predisposed her to both diseases.
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preventive measures are limited and unproven, such information
may cause more emotional distress than physical benefit.
The information itself may not reveal as much about predisposi-
tion to cancer as one may believe, due to either false positive or
false negative results, or simply the inexact nature of determining
the probability of disease onset. Moreover, until educational pro-
grams for health care providers are implemented, it is likely that
the physician who delivers genetic information to a patient's chil-
dren may not fully understand the meaning of the test results. The
chance that the disclosure of genetic information may deny individ-
uals health insurance, and thus access to the medical attention criti-
cal to preventing or treating cancer, threatens to cancel out any
benefit inured to a patient's child. Therefore, application of the
proposed balancing test would result in physician-patient confiden-
tiality outweighing a duty to warn the patient's children of their
risk of inheriting the BRCA mutations.
Conclusion
The ability to test for the BRCA1 or BRCA2 mutation is a sig-
nificant achievement of genetic scientists and marks the start of a
medical revolution. Such testing may provide those at risk for he-
reditary breast or ovarian cancer with invaluable information that
will enable them to better maintain health and an optimum quality
of life. It also threatens to cause serious harm, however, if offered
without assurances of effective treatment for the cancer, accurate
testing, adequately informed physicians, and protection against
discrimination.
Courts should adopt this balancing test because it takes these
important factors into account. Currently, application of the pro-
posed balancing test weighs against requiring physicians to warn a
patient's children that they may carry BRCA mutations, and leaves
the responsibility with the mother, who still knows best.
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